We developed a prediction model based on the 4 most powerful predictors of resistance to dopamine agonists being male gender, a great tumour volume, prolonged time to prolactin normalization and the existence of a cystic, hemorrhagic or necrotic component (before the start of the pharmacological treatment). The gene discussed is PRL; the disease is neoplasm.